CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain

CervoMed Inc. (NASDAQ: CRVO) reported initial data from its Phase 2a clinical trial indicating a reduction in mean plasma levels of neurofilament light chain (NfL) after 12 weeks of treatment with neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The results were presented at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia.